Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc., as indicated in the metadata request) for the period ending May 11, 2015, reporting events occurring on May 7, 2015. The filing primarily addresses corporate governance changes regarding the appointment of a new Chief Financial Officer (CFO) and the departure of the previous CFO.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Appointment of CFO: Jonathan Lloyd Jones was appointed as Chief Financial Officer, effective May 18, 2015.
- Departure of CFO: I. Richard Garr ceased his role as CFO effective May 18, 2015, though he retains his positions as CEO, General Counsel, President, and Board Member.
- Compensation Structure: The new CFO's compensation package includes a base salary of $315,000, a one-time inducement option for 50,000 shares, and eligibility for annual incentives up to 50% of base salary.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of operational risks. It notes that the new CFO has over 25 years of experience in corporate finance and business development, including prior roles at Columbia Laboratories (Juniper Pharmaceuticals) and TetraLogic Pharmaceuticals. The employment agreement includes severance provisions of one year's base salary and immediate vesting of the inducement option in the event of termination due to a change in control or for reasons other than cause.
Investor Verification Checklist
- Verify the effective date of the leadership transition (May 18, 2015).
- Review the attached Offer Letter (Exhibit 10.01) for full details on vesting schedules and bonus criteria.
- Confirm the continued role of I. Richard Garr as CEO and his oversight of financial duties during the transition.
- Note that no financial results or operational metrics are disclosed in this specific filing.